angiotensin ii has been researched along with ticlopidine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graciano, ML; Jackson, K; Kobori, H; Navar, LG; Nishiyama, A; Ortiz, RM; Prieto-Carrasquero, MC; Seth, DM | 1 |
| Carneiro, FS; Giachini, FR; Inscho, EW; Lima, VV; Osmond, DA; Tostes, RC; Webb, RC; Zhang, S | 1 |
| Du, J; Jia, L; Liu, O; Liu, X; Qin, Y; Wang, X; Wang, Y; Zhang, H | 1 |
| Cui, W; Du, J; Jia, LX; Li, TT; Liu, O; Qi, GM; Qi, YF; Yang, M; Zhang, WM | 1 |
| De Miguel, C; Inscho, EW; Osmond, DA; Pollock, JS; Yamamoto, T; Zhang, S | 1 |
5 other study(ies) available for angiotensin ii and ticlopidine
| Article | Year |
|---|---|
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
Topics: Actins; Adenosine Triphosphate; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Proliferation; Clopidogrel; Disease Models, Animal; Hypertension; Hypertrophy; Kidney; Male; Membrane Proteins; Mesangial Cells; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Sprague-Dawley; Receptors, Purinergic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Renin; Ticlopidine | 2008 |
Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.
Topics: Acetylcholine; Adenosine Diphosphate; Angiotensin II; Animals; Blotting, Western; Clopidogrel; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Ticlopidine; Vasodilation; Vasodilator Agents | 2010 |
Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Blood Platelets; Blood Pressure Determination; Clopidogrel; Cytokines; Immunoenzyme Techniques; Inflammation; Macrophages, Peritoneal; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Aggregation Inhibitors; Reactive Oxygen Species; Receptors, Purinergic P2Y12; Ticlopidine; Vasculitis; Vasoconstrictor Agents | 2012 |
Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.
Topics: Angiotensin II; Animals; Clopidogrel; Fibrosis; Hypertension; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocardium; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Transforming Growth Factor beta | 2013 |
Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension.
Topics: Angiotensin II; Animals; Clopidogrel; Hypertension; Kidney; Male; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12; Renal Circulation; Thromboxane B2; Ticlopidine | 2014 |